Persistence on warfarin in patients with atrial fibrillation: experience in Australia 2006-2009.
Long-term persistence on warfarin in patients with non-valvular atrial fibrillation is essential to minimise thromboembolic complications, especially ischaemic stroke. This study examines persistence in Australian patients with presumed atrial fibrillation newly prescribed warfarin. Longitudinal assessment of Pharmaceutical Benefit Scheme payment claim records from October 2006 through September 2009 in a 10% random sample of the Australian population holding long-term concession cards. proportion not filling first repeat prescription, median persistence time on medication, long-term persistence at 33 months. A total of 1 108 patients (representative of 11 080 nationally) were newly prescribed warfarin; mean age 74 years, 50% were females. Fifteen percent (95% CI: 13-17) failed to collect the first repeat prescription, median persistence time on medication was only 12 months (95% CI: 10-13), long-term persistence at 33 months was 26% (95% CI: 23-27). There is significant discontinuation of warfarin therapy. When due to non-compliance, an opportunity for stroke prevention is being lost.